{"prompt": "['Novartis', 'Confidential', 'Page 39', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', '5.5.9 Emergency breaking of assigned treatment code', 'Emergency code breaks must only be undertaken when it is required to in order to treat the', 'patient safely. Most often, study treatment discontinuation and knowledge of the possible', 'treatment assignments are sufficient to treat a study patient who presents with an emergency', 'condition. Emergency treatment code breaks are performed using the IRT. When the', 'investigator contacts the system to break a treatment code for a patient, he/she must provide', 'the requested patient identifying information and confirm the necessity to break the treatment', 'code for the patient. The investigator will then receive details of the investigational drug', 'treatment for the specified patient and a fax or email confirming this information. The system', 'will automatically inform the Novartis monitor for the site and the Study Team that the code', 'has been broken.', \"It is the investigator's responsibility to ensure that there is a dependable procedure in place to\", 'allow access to the IRT/code break cards at any time in case of emergency. The investigator', 'will provide:', 'protocol number', 'study drug name', 'patient number', 'In addition, oral and written information to the subject must be provided on how to contact', 'his/her backup in cases of emergency, or when he/she is unavailable, to ensure that un-', 'blinding can be performed at any time.', 'Study treatment must be discontinued if the treatment code of QVM149 treatment arm has', 'been broken (actual dose of QVM149 unblinded) after emergency unblinding or inadvertently', 'broken. This does not apply to the free triple treatment arm (salmeterol xinafoate/ : fluticasone', 'propionate + tiotropium) which is open label for investigators and patients.', '5.6 Study Completion and Discontinuation', '5.6.1 Study completion, post-study treatment and end of trial', 'A patient will be considered to have completed the study when the patient has completed the', 'last visit planned in the protocol (Visit 301).', 'Continuing care should be provided by investigator and/or referring physician based on', 'patient availability.', 'For all randomized patients, a safety follow-up Visit 301 should be conducted by telephone 7', 'days after last visit. The information to be collected at this follow up visit includes adverse', 'events and survival status.', 'The entire trial will be completed when the last randomized patient completes the last visit', '(Visit 301) of this protocol. In case the last patient randomized discontinues treatment', 'prematurely (see Section 5.6.2) or voluntarily withdraws consent (see Section 5.6.3) the', \"finalization of the trial is considered at patient's last visit. The trial will also end if Novartis is\", 'terminating the trial due to reasons related to benefit/risk assessment (see Section 5.6.5).']['Novartis', 'Confidential', 'Page 40', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', '5.6.2 Discontinuation of Study Treatment', 'Discontinuation of study treatment for a patient occurs when study drug is stopped earlier than', 'the protocol planned duration, and can be initiated by either the patient or the investigator. In', 'such cases the patient should be asked to continue in the trial through the scheduled final visit', 'in order to ensure the scientific integrity of the trial.', 'The investigator must discontinue study treatment for a given patient if, on balance, he/she', 'believes that continuation of study treatment would negatively impact the risk/benefit of trial', 'participation.', 'Study treatment must be discontinued under the following circumstances:', 'Patient wish', 'Pregnancy', 'Any situation in which study treatment might result in a safety risk to the patient', 'If discontinuation of study treatment occurs, the patient should NOT be considered withdrawn', 'from the study. For this study it is very important to continue collecting data on all patients', 'that discontinue treatment, especially for primary endpoint and safety. The patient should', 'return to the clinic as soon as possible, after discontinuation of study drug, for a study', 'treatment discontinuation visit. Treatment discontinuation visit assessments detailed in Table', '6-1 should be completed and recorded in the eCRF. The investigator must determine the', \"primary reason for the patient's premature discontinuation of study treatment and record this\", 'information in the End of Study Treatment eCRF. The investigator and study staff must also', 'discuss continued participation with the patient.', 'Patients who discontinue study treatment prematurely should continue with limited study', 'assessments. They should return to the clinic for each scheduled visit during the treatment', 'period according to Assessment Schedule Table 6-1 but only conduct the assessments', 'indicated in Table 5-5 Assessments for Patients who Discontinue Study Treatment. Patients', 'should also conduct the safety follow-up Visit 301 (via telephone) after completing the', 'intended treatment period.', 'Table 5-5 Assessments for Patients who Discontinue Study Treatment', 'Assessment', 'AQLQ\u00b9', 'Spirometry1', 'Record AEs', 'Record SAEs', 'Record Asthma Exacerbations', 'Review Concomitant Medication', 'Review Surgery and Procedures', '1 PROs should be completed before any other assessment. AQLQ and Spirometry must be performed pre-dose', 'for standard of care treatment.', \"The investigator must also contact the IRT to register the patient's discontinuation from study\", 'treatment. If study drug discontinuation occurs because treatment code of QVM149 treatment', 'arm has been broken (actual dose of QVM149 unblinded), please refer to Section 5.5.9.']\n\n###\n\n", "completion": "END"}